MAX REINHARDT - 18 Apr 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: President, Rest of World
Signature: /s/ Kristen Williams, Attorney-in-Fact
Issuer symbol: PCRX
Transactions as of: 18 Apr 2022
Net transactions value: -$458,241
Form type: 4
Filing time: 20 Apr 2022, 20:25:08 UTC
Previous filing: 06 Jul 2021
Next filing: 25 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCRX	Common Stock	Options Exercise	$531,750	+12,500	+71%	$42.54	30,000	18 Apr 2022	Direct	F1
transaction	PCRX	Common Stock	Sale	$657,611	-8,941	-30%	$73.55	21,059	18 Apr 2022	Direct	F1, F2
transaction	PCRX	Common Stock	Options Exercise	$531,750	+12,500	+59%	$42.54	33,559	19 Apr 2022	Direct	F1
transaction	PCRX	Common Stock	Sale	$673,442	-9,321	-28%	$72.25	24,238	19 Apr 2022	Direct	F1, F2, F3
transaction	PCRX	Common Stock	Options Exercise	$531,750	+12,500	+52%	$42.54	36,738	20 Apr 2022	Direct	F1
transaction	PCRX	Common Stock	Sale	$722,438	-9,764	-27%	$73.99	26,974	20 Apr 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCRX	Stock Option (Right to Buy)	Options Exercise	$0	-12,500	-8.3%	$0.000000	137,500	18 Apr 2022	Common Stock	12,500	$42.54	Direct	F4
transaction	PCRX	Stock Option (Right to Buy)	Options Exercise	$0	-12,500	-9.1%	$0.000000	125,000	19 Apr 2022	Common Stock	12,500	$42.54	Direct	F4
transaction	PCRX	Stock Option (Right to Buy)	Options Exercise	$0	-12,500	-10%	$0.000000	112,500	20 Apr 2022	Common Stock	12,500	$42.54	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2	Represents shares sold by the reporting person to cover the (i) exercise price of stock options and (ii) tax obligations due upon the exercise of such stock options.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.01 to $72.55, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4	The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.